Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib

Human estrogen receptor positive cancer cells have mutations and make an excess of the HER2 protein and are far more aggressive than others cancers. Neratinib, an irreversible tyrosine kinase inhibitor is used to treat HER2 positive cancers. Neratinib targets HER2 and blocks its signal transduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhezayem, Sara, Wani, Tanveer A., Wakil, Salma, Aljuraysi, Ashwaq, Zargar, Seema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414076/
https://www.ncbi.nlm.nih.gov/pubmed/32792841
http://dx.doi.org/10.1016/j.jsps.2020.06.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414076/
https://www.ncbi.nlm.nih.gov/pubmed/32792841
http://dx.doi.org/10.1016/j.jsps.2020.06.017

Ejemplares similares